Markets

CorMedix (CRMD) in Focus: Stock Adds 16.3% in Session

CorMedix, Inc.CRMD was a big mover last session, as its shares rose over 16% on the day. The upside was driven by the announcement of enrollment and dosing of the first patient in the LOCK-IT-100 (Catheter Lock Solution Investigational Trial) Phase 3 clinical study. This also led to far more shares changing hands than in a normal session. Yesterday's rally reverses the recent downtrend for the company, as the stock is now down over 13% in the past one-month time frame.

Over the last 30 days, the company witnessed one negative estimate revision and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher lasts.

CorMedix currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

A better-ranked biomedical stock is Anika Therapeutics Inc. ANIK with a Zacks Rank #1 (Strong Buy).

Is PBYI going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

CORMEDIX INC (CRMD): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ANIK CRMD

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More